Medill Reports: ChicagoAbbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter …MarketWatch (press release)Abbott's partnership with Biogen Idec includes development of a novel, next-generation antibody, daclizumab, which i…
ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its …SunHerald.comToday NHL is frequently treated with the anticancer antibody, rituximab (Rituxan®), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, conta…
IMMUNOGEN, INC. : Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its …4-tradersToday NHL is frequently treated with the anticancer antibody, rituximab (Rituxan®), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, contain…
ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its …MarketWatch (press release)Today NHL is frequently treated with the anticancer antibody, rituximab (Rituxan(R)), and/or with chemotherapy. The novel agent IMGN529, a TAP …
UCSD to build biotech incubatorU-T San DiegoFor example, rituximab, developed for treatment of patients with B cell malignancies, now also is being used to treat patients with rheumatoid arthritis. Q: Will there be anything special about the design of …
Cimzia (certolizumab pegol) shows positive top-line phase 3 results in axial …PharmaLive.com (press release)Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events see…
Pharmazeutische Zeitung onlineBelatacept: Nutzenbewertung des IQWiG liegt vorPharmazeutische Zeitung onlineBeide Gruppen erhielten zusätzlich Corticosteroide, Mycophenolat und zu Therapiebeginn zudem den Antikörper Basiliximab. In Bezug auf Sterblich…
Biogen's Fampyra Launched in Canada – Analyst BlogNASDAQBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen recently signed an exclusive,…
Biogen's Fampyra Launched In CanadaDaily MarketsBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen recently signed an exclusive, worl…
Biogen's Fampyra Launched in CanadaZacks.comBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (ABT), and PEGylated interferon. Biogen recently signed an exclusive, worldwide opt…